A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)

Completed · Phase 3

Conditions studied: Acne Vulgaris

In brief

This is a multi-center, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, efficacy, and tolerability of IDP-123 Lotion in comparison with IDP-123 Vehicle Lotion.

Key facts

Study ID

NCT03168334

Run by

Bausch Health Americas, Inc.

People needed

801

Starts

2017-07-11

Expected to finish

2018-07-24

Last updated by the study team

2021-04-01

Who can join

Age: 9 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female at least 9 years of age and older;
• Written and verbal informed consent must be obtained. Subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches age of consent during the study they should be re-consented at the next study visit);
• Subject must have a score of 3 (moderate) or 4 (severe) on the Evaluator's Global Severity assessment at the baseline visit;
• Subjects with facial acne inflammatory lesion (papules, pustules, and nodules) count no less than 20 but no more than 50;
• Subjects with facial acne non-inflammatory lesion (open and closed comedones) count no less than 25 but no more than 100;
• Subjects with two or fewer facial nodules

You may not qualify if…

• Use of an investigational drug or device within 30 days of enrollment or participation in a research study concurrent with this study;
• Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gram-negative folliculitis, dermatitis, eczema;
• Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive;
• Subjects with a facial beard or mustache that could interfere with the study assessments;
• Subjects with more than two (2) facial nodules;
• Evidence or history of cosmetic-related acne

Where it is running

• Valeant Site 41 — Mobile, Alabama, United States
• Valeant Site 22 — Rogers, Arkansas, United States
• Valeant Site 34 — Carlsbad, California, United States
• Valeant Site 12 — Fremont, California, United States
• Valeant Site 06 — San Diego, California, United States
• Valeant Site 13 — San Diego, California, United States
• Valeant Site 31 — San Diego, California, United States
• Valeant Site 36 — Santa Ana, California, United States
• Valeant Site 25 — Denver, Colorado, United States
• Valeant Site 05 — Boynton Beach, Florida, United States
• Valeant Site 29 — Clearwater, Florida, United States
• Valeant Site 38 — Jupiter, Florida, United States
• Valeant Site 02 — Miami, Florida, United States
• Valeant Site 26 — West Palm Beach, Florida, United States
• Valeant Site 44 — Snellville, Georgia, United States
• Valeant Site 32 — Louisville, Kentucky, United States
• Valeant Site 19 — Rockville, Maryland, United States
• Valeant Site 08 — Bay City, Michigan, United States
• Valeant Site 30 — Clarkston, Michigan, United States
• Valeant Site 37 — Clinton Township, Michigan, United States
• Valeant Site 20 — Fort Gratiot, Michigan, United States
• Valeant Site 24 — Fridley, Minnesota, United States
• Valeant Site 03 — Morristown, New Jersey, United States
• Valeant Site 42 — Albuquerque, New Mexico, United States
• Valeant Site 10 — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.